Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 31.08.2026 1 Am J Clin Oncol 2 Ann Surg Oncol 1 Ann Thorac Surg 1 BMC Cancer 1 Cancer Lett 3 Clin Lung Cancer 1 Clin Nucl Med 2 Eur J Cancer 1 Int J Cancer 1 J Cancer Res Clin Oncol 3 J Clin Oncol 1 J Nucl Med 2 J Thorac Cardiovasc Surg 1 J Thorac Oncol 2 Lancet Oncol 3 Lung Cancer 1 Oncogene 2 Oncol Rep 1 Oncologist 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. NEELESH BT, Bhardwaj K, Mn P, Padhiar C, et al
   Genetic Alterations in NSCLC: Prognostic Implications and Impact on Therapeutic Resistance.
   Am J Clin Oncol. 2026;49:458-464.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. AKAMINE T, Hino T, Shimokawa M, Hida T, et al
   Fibrotic Interstitial Lung Abnormalities on Preoperative CT Images Predict Cause-Specific Mortality after Stage I Non-Small Cell Lung Cancer Resection.
   Ann Surg Oncol. 2026 Aug 25. doi: 10.1245/s10434-026-20495.
   PubMed         Abstract available
   
   
3. WROBEL D, Rogaczewski P, Dabrowski P, Olejek W, et al
   Complete Resection of Simultaneous Hepatic and Pulmonary Metastases from Colorectal Cancer in the Era of Modern Systemic and Surgical Therapies: A Systematic Review and Meta-Analysis.
   Ann Surg Oncol. 2026 Aug 22. doi: 10.1245/s10434-026-20323.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

4. KURODA S, Shomoto T, Nishioka Y, Shimizu N, et al
   Pulmonary Artery-Bronchial Territory Mismatch in Segmentectomy and Its Effect on Surgical Resection Margins.
   Ann Thorac Surg. 2026;122:703-710.
   PubMed         Abstract available
   
   

   
   BMC Cancer

5. YIN S, Hu T, Li X, Xu D, et al
   Distinct epidemiologic patterns of mesothelioma: evidence from a 16-year provincial cohort in China.
   BMC Cancer. 2026;26:1012.
   PubMed         Abstract available
   
   

   
   Cancer Lett

6. SUN BB, Wang GZ, Han SC, Yang FY, et al
   Corrigendum to "Oncogenic functions and therapeutic potentials of targeted inhibition of SMARCAL1 in small cell lung cancer" [Cancer Lett. 592, (2024), 216929].
   Cancer Lett. 2026 Aug 29:218793. doi: 10.1016/j.canlet.2026.218793.
   PubMed        
   
   

   
   Clin Lung Cancer

7. POTUGARI B, Gupta J, Bachler J, Wang A, et al
   Impact of Socioeconomic Status on Patient-Reported Outcomes (PROs) in Non-Small-Cell Lung Cancer (NSCLC).
   Clin Lung Cancer. 2026;27:136-141.
   PubMed         Abstract available
   
   
8. WANG J, Lu Z, Ge M, Zhang X, et al
   Integrated Genomic and Immune Profiling of Early Onset Lung Cancer in East Asians Reveals a Distinct Molecular Architecture.
   Clin Lung Cancer. 2026;27:129-135.
   PubMed         Abstract available
   
   
9. COLOMINA JH, Parreira A, Al-Hamami SS, Sereno M, et al
   Real-world Safety and Effectiveness of Neoadjuvant Chemoimmunotherapy in Squamous Cell Lung Cancer: A Retrospective European Multicenter Study.
   Clin Lung Cancer. 2026;27:142-148.
   PubMed         Abstract available
   
   

   
   Clin Nucl Med

10. CHENG Y, Qin T, Yang F, Lu K, et al
    Comparison of the Prognostic Value of PET Metabolic Parameters and Postoperative Pathologic Response After Neoadjuvant Immunochemotherapy in Non-Small Cell Lung Cancer.
    Clin Nucl Med. 2026 Aug 24. doi: 10.1097/RLU.0000000000006675.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

11. MOLINA-VILA MA, Tsourti Z, Vervita K, Bertran-Alamillo J, et al
    Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project.
    Eur J Cancer. 2026;245:116583.
    PubMed         Abstract available
    
    
12. DE MEO M, Siringo M, Gandini O, Gareri R, et al
    Organotropism-specific circulating tumor cells profiles: Morphology and heterotypic clustering predict metastatic sites in liquid biopsy of solid tumors.
    Eur J Cancer. 2026;245:116934.
    PubMed         Abstract available
    
    

    
    Int J Cancer

13. KUSEL-KANBACH J, Riedel O, Haug U
    Comparison of Healthcare Utilization Before Diagnosis Between Non-Advanced and Advanced Lung Cancer Patients: A Study Among 72,851 Cases in Germany.
    Int J Cancer. 2026 Aug 27. doi: 10.1002/ijc.70682.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

14. ABEL JOPAUL VP, Lingaraj M
    Comment on "Artificial intelligence construction: a review of the bridge between CT imaging features of lung ground-glass nodules adenocarcinoma and carcinogenic driver genes".
    J Cancer Res Clin Oncol. 2026;152:167.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

15. TANIZAKI J
    Targeting ErbB-Family Receptors in Small Cell Lung Cancer: Clinical Activity and an Unresolved Mechanism.
    J Clin Oncol. 2026 Aug 27:JCO2601469. doi: 10.1200/JCO-26-01469.
    PubMed        
    
    
16. DAGOGO-JACK I
    Speeding to a Stop: Postapproval Barriers to Accessing New Lung Cancer Therapies.
    J Clin Oncol. 2026 Aug 27:JCO2601480. doi: 10.1200/JCO-26-01480.
    PubMed        
    
    
17. HEYMACH JV, He J, Harpole D, Mitsudomi T, et al
    Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.
    J Clin Oncol. 2026 Aug 28:JCO2502659. doi: 10.1200/JCO-25-02659.
    PubMed         Abstract available
    
    

    
    J Nucl Med

18. ZHOU J, Liu Y, Zhou M, Hai W, et al
    [(68)Ga]Ga-NODAGA-SNA006 PET/CT Reveals CD8(+) T-Cell Dynamics in Lung Cancer Progression and Anti-PD-1 Response.
    J Nucl Med. 2026 Aug 27:jnumed.125.271377. doi: 10.2967/jnumed.125.271377.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

19. KATTA M, Puri V
    Commentary: Surveillance with Purpose: Guideline Adherence After Lung Cancer Treatment and Its Impact on Survival.
    J Thorac Cardiovasc Surg. 2026 Aug 28:S0022-5223(26)01240.
    PubMed        
    
    
20. SUZUKI K
    Commentary: Title Lobectomy Improves Disease-Free Survival Over Sublobar Resection for High-Risk Stage IA Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2026 Aug 28:S0022-5223(26)01237.
    PubMed        
    
    

    
    J Thorac Oncol

21. WU F, Zhang W, Zhao Y, Yu Y, et al
    Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.
    J Thorac Oncol. 2026 Aug 24:104165. doi: 10.1016/j.jtho.2026.104165.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

22. DZIADZIUSZKO R, Ahn JS, Barlesi F, Solomon BJ, et al
    Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2026;27:1110-1119.
    PubMed         Abstract available
    
    
23. LE X, Passaro A, Zhao Y, Huang Y, et al
    Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, ph
    Lancet Oncol. 2026;27:1094-1109.
    PubMed         Abstract available
    
    

    
    Lung Cancer

24. OMORI S, Kenmotsu H, Nomura S, Harada H, et al
    Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial.
    Lung Cancer. 2026;220:109583.
    PubMed         Abstract available
    
    
25. KIM HS, Zhang L, Bodor JN, Clapper ML, et al
    The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC).
    Lung Cancer. 2026;220:109582.
    PubMed         Abstract available
    
    
26. GIRARD N, Carton M, Macouillard P, Debieuvre D, et al
    Treatment patterns and outcomes in advanced and metastatic lung cancer in France: Results from the Epidemiological Strategy and medical Economics (ESME) database lung cancer in France.
    Lung Cancer. 2026;220:109585.
    PubMed         Abstract available
    
    

    
    Oncogene

27. ZHANG M, Zhu J, Zhang H, Zhang J, et al
    N6-methyladenosine-mediated upregulation of PAICS promotes lung-adenocarcinoma metastasis via the integrin-FAK signaling.
    Oncogene. 2026;45:3633-3646.
    PubMed         Abstract available
    
    

    
    Oncol Rep

28. WANG L, Feng Y, Liu Q
    Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non?small cell lung cancer (Review).
    Oncol Rep. 2026;56:182.
    PubMed         Abstract available
    
    
29. ZHANG Y, Shang Y, Zeng H, Ning R, et al
    Research progress on lactate metabolism in lung cancer: Tumorigenesis, drug resistance and clinical translation (Review).
    Oncol Rep. 2026;56:181.
    PubMed         Abstract available
    
    

    
    Oncologist

30. YANG X, Tan Q, Chen S, Xie J, et al
    Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study.
    Oncologist. 2026 Aug 27:oyag344. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

31. WU P, Zhou X
    Canon enables causal inference of downstream genes in single-cell CRISPR studies via instrumental variable analysis.
    Proc Natl Acad Sci U S A. 2026;123:e2525359123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum